Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chiglitazar Sodium for NAFLD with Type 2 Diabetes Mellitus
ChiCTR2200064367Phase 4Not yet recruiting
- Sponsor
- Shanghai Fifth People's Hospital
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes mellitus (T2DM) comparing Chiglitazar sodium 48 mg + lifestyle intervention with Placebo + lifestyle intervention (2 arms). Primary endpoint: FibroScan-AST (FAST) score. Planned start Sep 2022; status: not yet recruiting.
02
Drugs
chiglitazar
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2200064367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200064367.